

## Special Issue

# Pandemic Influenza Vaccination

### Message from the Guest Editors

Pandemic influenza vaccines are crucial tools in mitigating the impact of influenza pandemics. These vaccines can also play an important role during the interpandemic period to prevent zoonotic infection with H5 viruses in populations at elevated risk and to respond to isolated outbreaks. The 2009 influenza pandemic and the more recent COVID-19 pandemic have highlighted the importance of pandemic planning and preparedness; this includes having an updated national pandemic plan as well as a deployment and vaccination plan. This also includes strengthening national capacities for the early detection, research, regulatory approval, rollout, and monitoring of pandemic influenza vaccinations. These capacities are crucial for an effective and timely response to an influenza pandemic. In light of the above, this Special Issue will have two significant emphases: 1. the development, production, licensing, and procurement of influenza vaccines; 2. influenza vaccinations during epidemics and pandemics, including preparing for and delivering successful campaigns.

---

### Guest Editors

Dr. Francisco Nogareda

Special Program Comprehensive Immunization, Pan American Health Organization (PAHO)/World Health Organization (WHO), Washington, DC 20037, USA

Dr. Shoshanna Goldin

World Health Emergencies Program, World Health Organization (WHO), 1211 Geneva, Switzerland

---

### Deadline for manuscript submissions

closed (31 March 2026)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.5  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/si/229421](https://mdpi.com/si/229421)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.5  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

---

### Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College  
Roosevelt, 4331 CB Middelburg, The Netherlands

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Infectious Diseases)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).